In This Issue:
- Ask A Doctor
- ELHA Lab Profile: Bridging Science and Community
- New Addition to the Easton Center
- Clinical Trials
- Upcoming Events
The Mary S. Easton Center for Alzheimer’s Research and Care at UCLA has very active teams working on basic research, drug discovery, biomarkers for early diagnosis and clinical activity including clinical trials, cognitive testing, and patient care.
Ask A Doctor
By: Alejandra Sánchez López, MD, Assistant Clinical Professor of Neurology and Geriatric Medicine Division at UCLA
Lecanemab is a new medication for the treatment of early Alzheimer’s disease. In this newsletter's “Ask the Doctor” section, Dr. Sánchez López answers common questions we receive from patients about lecanemab.
1. What is {LECANEMAB}, and how does it work?
Lecanemab, also known by the brand name Leqembi®, is an anti-amyloid monoclonal antibody approved by the FDA in January 2023 for treating the early stages of Alzheimer’s disease.
Two proteins, amyloid beta, and tau, accumulate in the brains of people with Alzheimer’s disease. These proteins are toxic to the brain and cause neuronal loss. Lecanemab binds selectively to aggregated forms of amyloid beta to help the immune system remove it from the body.
Watch the Video: https://youtu.be/BFE8nOyKwhQ?si=oxqibG1LpHZ527x-
